Lite Strategy, Inc. Restructuring Costs
Lite Strategy, Inc. (LITS) reported Restructuring Costs of $2.60 million for the 12-month period ending 2023-06-30, per its 10-K filed 2023-09-26.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:RestructuringCosts · last filed 2023-09-26
- Lite Strategy, Inc. restructuring costs for fiscal 2023 was $2.60M.
| Period end | Restructuring Costs 12 month |
|---|---|
| 2023-06-30 | $2.60M 10-K · filed 2023-09-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |